Motley Fool
Is Keryx Biopharmaceuticals Burning Too Much Cash?
What is Keryx's burn rate, and how much cash does it have on hand?
1 Easy Way Steve Jobs Could Have Done Even More
Steve Jobs certainly didn't need to do more. He accomplished more than most could ever dream of. However, there is another way he could have done even more good at almost no cost to him.
Tackling Cancer: Leukemia's Biggest Current and Upcoming Players
Cancer research is big business, and it pays to know where research dollars are headed.
1 Simple Reason the Google Stock Rally Will Continue
A Fool bets real money in a three-year tussle with Mr. Market.
Heckmann Picks a New Name
And will begin answering to it at the opening bell on Monday.
Forget What You've Heard: Reed Hastings Is Still a Recluse
Netflix has barely begun to meet its social media potential.
Why Ford Is Losing Big in India
Despite its success in places like China and Russia, Ford is fast falling behind in India. Here's what Ford is doing to hang on in this huge emerging market.
Why Boston Beer Stumbled
What tripped up Boston Beer this earnings season?
Microsoft Sets New 52-Week High! Should You Buy, Sell, or Hold?
A quick look at whether investors should be buying, selling, or holding shares of Microsoft now that it is up more than 30% year-to-date.
1 Great Dividend You Can Buy Right Now
This stocks yield may not be a jaw-dropper yet, but it's positioned "purrrrrfectly" in a rapidly growing sector to deliver long term profits and payouts.
GM's Big Push in Brazil
General Motors has had a presence in Brazil for ages, but lately, its position in this fast-growing market has come under pressure. Here's how GM plans to respond.
The Case-Shiller CAPE Is Obsolete (At Least for Now)
Distortions in this widely cited metric, make it practically useless for investors.
"Game of Thrones" Is Worth So Much More Than You Think
The cable network doesn’t need to spin-off HBO GO to profit.
The 3 Deadliest Diseases in the U.S.
These deadly diseases kill more than 1 million Americans every year. But there's still some good news.
GM Is Losing Down Under
General Motors' Australian operation is losing money, thanks to cheap imports. Sound familiar? Here's what GM is doing about it.
Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Started
Biogen's MS drug is off to a hot start, and its new hemophilia drugs are under FDA review.
How to Play the E-Commerce Trend in China
You know it's big. You know it's growing. Now we'll tell you how to profit from it.
5 American Cities With a Booming Manufacturing Industry
Once left for dead, this industry has been making a comeback.
Will Any Dell Stock Owners Take Carl Icahn's Money?
Carl Icahn wants to give Dell stock owners $12 each. However, his plan may unravel if he convinces too many people that the company is massively undervalued.


